{
    "2019-03-12": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Eli Lilly (LLY) Flat As Market Gains: What You Should Know",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Flat",
                        "Market Gains"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Eli Lilly’s Latest Move Proves the American Healthcare System Is Broken",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "American Healthcare",
                        "Broken"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "BioNtech hires banks for IPO worth up to $800 million - sources",
                "features": {
                    "keywords": [
                        "BioNtech",
                        "IPO",
                        "$800 million"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Biontech stock offering could be worth as much as $800 million-sources",
                "features": {
                    "keywords": [
                        "Biontech",
                        "stock offering",
                        "$800 million"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Allergan Announces FDA Acceptance of Migraine Candidate NDA",
                "features": {
                    "keywords": [
                        "Allergan",
                        "FDA",
                        "Migraine",
                        "NDA"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Industry-Leading Growth",
                        "JPMorgan"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "See what the IHS Markit Score report has to say about Eli Lilly and Co.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Why Eli Lilly Stock Fell Yesterday",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Stock Fell"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Here are the biggest analyst calls of the day: Tesla, Boeing, Coca-Cola, Monster Beverage, Eli Lilly",
                "features": {
                    "keywords": [
                        "analyst calls",
                        "Tesla",
                        "Boeing",
                        "Coca-Cola",
                        "Monster Beverage",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "various"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "Lilly's combo therapy succeeds in late-stage lung cancer study",
                "features": {
                    "keywords": [
                        "Lilly",
                        "combo therapy",
                        "lung cancer",
                        "study"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-13",
                "original_text": "Lilly's combo treatment meets main goal in lung cancer late-stage study",
                "features": {
                    "keywords": [
                        "Lilly",
                        "combo treatment",
                        "lung cancer",
                        "late-stage study"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-14",
                "original_text": "Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer",
                "features": {
                    "keywords": [
                        "CYRAMZA",
                        "Phase 3",
                        "RELAY Trial",
                        "Progression-Free Survival",
                        "Non-Small Cell Lung Cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-15",
                "original_text": "Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript",
                "features": {
                    "keywords": [
                        "Dicerna Pharmaceuticals",
                        "Q4 2018",
                        "Earnings",
                        "Conference Call"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}